Your browser doesn't support javascript.
loading
Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population.
Díaz-Acedo, Rocío; Artacho Criado, Silvia; Jiménez Galán, Rocío; Gutiérrez Pizarraya, Antonio; Galván Banqueri, Mercedes; Rodríguez-de-la-Borbolla-Artacho, María; Marcos Rodríguez, José Antonio; Márquez Saavedra, Esther.
Afiliação
  • Díaz-Acedo R; Pharmacy Department, 16583Universitary Hospital of Valme, Spain.
  • Artacho Criado S; Pharmacy Department, 16583Universitary Hospital of Valme, Spain.
  • Jiménez Galán R; Pharmacy Department, 16885Universitary Hospital Virgen del Rocío, Spain.
  • Gutiérrez Pizarraya A; Pharmacy Department, 16583Universitary Hospital of Valme, Spain.
  • Galván Banqueri M; Pharmacy Department, 16583Universitary Hospital of Valme, Spain.
  • Rodríguez-de-la-Borbolla-Artacho M; Medical Oncology Department, Universitary Hospital of Valme, Spain.
  • Marcos Rodríguez JA; Pharmacy Department, 16582Universitary Hospital Virgen Macarena, Spain.
  • Márquez Saavedra E; Pharmacy Department, 16583Universitary Hospital of Valme, Spain.
J Oncol Pharm Pract ; 28(7): 1573-1582, 2022 Oct.
Article em En | MEDLINE | ID: mdl-34558360
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antineoplásicos Tipo de estudo: Observational_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antineoplásicos Tipo de estudo: Observational_studies Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2022 Tipo de documento: Article